Abstract 2255: Evaluation of the Diagnostic Value of Serum Anti-Cyclin B1 Autoantibody As a Biomarker in Lung Cancer
Mengtao Xing,Pei Li,Jianxiang Shi,Liping Dai,Jitian Li,Jianying Zhang
DOI: https://doi.org/10.1158/1538-7445.am2016-2255
IF: 11.2
2016-01-01
Cancer Research
Abstract:Abstract To detect the diagnostic value of cancer-associated autoantibodies in lung cancer, a panel of 9 tumor-associated antigens (TAAs) were used in this study. The TAAs were composed of p62, p16, Koc, p53, Cyclin B1, Cyclin E, Survivin, HCC1, and Rol-A full-length recombinant proteins. Enzyme-linked immunosorbent assay and immunoblotting were used to detect antibodies in 50 lung cancer sera with clinicopathological characteristics and 42 sera from normal individuals. Following, antibodies to Cyclin B1, survivin, p53 and HCC1 were selected and confirmed in another 62 sera from patients with lung cancer but without clinical date and evaluate the diagnostic value of these TAAs. The results showed that the positive rate of autoantibodies against nine selected TAAs (cyclin B1, survivin, HCC1,p53, KOC,p16,p62, RalA and cyclin E) reached 36%, 36%, 26%, 12%, 8%, 6%, 6%, 2%, 0% in 50 lung cancer sera and 4.8%, 2.4%, 0%, 0%, 2.4%, 4.8%, 2.4%, 2.4%, 4.8% in 42 normal sera, respectively. The AUC values for distinguishing lung cancers from normal sera were 0.767, 0.400, 0.567, 0.395, 0.230, 0.517, 0.635, 0.194, 0.411, respectively. These data suggest that cyclin B1, survivin, HCC1 and p53 has higher clinical diagnostic quality and value than other TAAs in lung cancer. In the confirmation group with 62 lung cancer sear, autoantibodies against these four TAAs were also significantly higher in patients with lung cancer (AUC values of 0.764,0.653,0.623 and 0.622, p<0.05). Evaluation of the diagnostic value of these four TAAs in 50 sera from lung cancer patients with clinical characteristics, and results revealed that serum anti-cyclin B1, anti-survivin and anti-p53 autoantibodies significantly increased in patients with stage I but only serum anti-cyclin B1 increased in stage II and III lung cancer (p <0.05, respectively), ROC curve analysis has shown that anti-cyclin B1 and anti-p53 autoantibodies can discriminate stage I lung cancer from normal controls with AUC value of 0.757,0.697, respectively (p<0.01), and anti-survivin and anti-HCC1 autoantibodies failed to discriminate stage I lung cancer from normal controls. Our results suggest that these four TAAs has higher clinical diagnostic quality and value than other TAAs in lung cancer and serum cyclin-B1 may have the potential to serve as novel non-invasive diagnostic biomarkers in patients with lung cancer, especially in early stage lung cancer. Citation Format: Mengtao Xing, Pei Li, Jianxiang Shi, Liping Dai, Jitian Li, Jianying Zhang. Evaluation of the diagnostic value of serum anti-cyclin B1 autoantibody as a biomarker in lung cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2255.